These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37241097)

  • 1. Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis.
    Fedičová M; Mikula P; Gdovinová Z; Vitková M; Žilka N; Hanes J; Frigová L; Szilasiová J
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241097
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients.
    Szilasiová J; Rosenberger J; Fedičová M; Mikula P; Urban P; Gdovinová Z; Vitková M; Hanes J; Stevens E
    Eur Neurol; 2021; 84(4):272-279. PubMed ID: 34034261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Szilasiová J; Mikula P; Rosenberger J; Fedičová M; Gdovinová Z; Urban P; Frigová L
    Mult Scler; 2021 Nov; 27(13):2023-2030. PubMed ID: 33635154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis.
    Szilasiova J; Mikula P; Rosenberger J; Fedicova M; Urban P; Frigova L; Vitkova M; Gdovinova Z; Hanes J; Stevens E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep; 166(3):304-311. PubMed ID: 34092793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
    Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
    Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S; Comi G; Cree BAC; Arnold DL; Steinman L; Sheffield JK; Southworth H; Kappos L; Cohen JA;
    Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
    Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of the Lumipulse™ immunoassay for plasma neurofilament light chain in multiple sclerosis.
    Nicolella V; Fiorenza M; Monteiro I; Novarella F; Sirica R; D'Angelo M; Carbone G; La Civita E; Esposito A; Criscuolo V; Carotenuto A; Petracca M; Lanzillo R; Castaldo G; Morra VB; Terracciano D; Moccia M
    J Neurol Sci; 2024 Aug; 463():123115. PubMed ID: 38964268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis.
    Manouchehrinia A; Stridh P; Khademi M; Leppert D; Barro C; Michalak Z; Benkert P; Lycke J; Alfredsson L; Kappos L; Piehl F; Olsson T; Kuhle J; Kockum I
    Neurology; 2020 Jun; 94(23):e2457-e2467. PubMed ID: 32434867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.
    Seiberl M; Feige J; Hilpold P; Hitzl W; Machegger L; Buchmann A; Khalil M; Trinka E; Harrer A; Wipfler P; Moser T
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study.
    Vacchiano V; Mastrangelo A; Zenesini C; Masullo M; Quadalti C; Avoni P; Polischi B; Cherici A; Capellari S; Salvi F; Liguori R; Parchi P
    Front Aging Neurosci; 2021; 13():753242. PubMed ID: 34744694
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
    Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
    Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort.
    Steffen F; Uphaus T; Ripfel N; Fleischer V; Schraad M; Gonzalez-Escamilla G; Engel S; Groppa S; Zipp F; Bittner S
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy.
    Maia LF; Maceski A; Conceição I; Obici L; Magalhães R; Cortese A; Leppert D; Merlini G; Kuhle J; Saraiva MJ
    Amyloid; 2020 Jun; 27(2):97-102. PubMed ID: 31906707
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
    Pauwels A; Van Schependom J; Devolder L; Van Remoortel A; Nagels G; Bjerke M; D'hooghe MB
    Mult Scler; 2022 Oct; 28(11):1685-1696. PubMed ID: 36059263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients.
    Ferraro D; Guicciardi C; De Biasi S; Pinti M; Bedin R; Camera V; Vitetta F; Nasi M; Meletti S; Sola P
    Acta Neurol Scand; 2020 Jan; 141(1):16-21. PubMed ID: 31350854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study.
    Peng L; Wan L; Liu M; Long Z; Chen D; Yuan X; Tang Z; Fu Y; Zhu S; Lei L; Wang C; Peng H; Shi Y; He L; Yuan H; Wan N; Hou X; Xia K; Li J; Chen C; Qiu R; Tang B; Chen Z; Jiang H
    J Neurol; 2023 Sep; 270(9):4248-4261. PubMed ID: 37184660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Neurofilament Light Is Not Associated with Ongoing Neuroaxonal Injury or Cognitive Decline in Perinatally HIV Infected Adolescents: A Brief Report.
    van der Post J; van Genderen JG; Heijst JA; Blokhuis C; Teunissen CE; Pajkrt D
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.